Inilah fakta-fakta yang tidak diketahui oleh para kritikus aktivis terhadap CEO Pfizer, Albert Bourla, menurut analisis dari Yale.
with 19 of them in late-stage development. These candidates cover a wide range of therapeutic areas, from oncology and rare diseases to inflammation and immunology. Additionally, Pfizer has made significant progress in its digital health initiatives, with investments in telemedicine and remote patient monitoring. The company’s commitment to innovation and diversification ensures a strong foundation … Baca Selengkapnya